Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?

Marticorena, Joaquín; Romano, Mario R.; Heimann, Heinrich; Stappler, Theodor; Gibran, Kurshid S; Groenewald, Carl; Pearce, Ian; Wong, David

doi:10.1136/bjo.2009.177287

Cited by 19 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it is indicated that maintaining a normal balance between antiangiogenic and proangiogenic VEGFs (VEGF 165/VEGF165b) would be more suitable approach instead of only targeting proangiogenic VEGFs. [3233]…”

mentioning

confidence: 99%

Managing patients with retinal vein occlusions: Is there any real step forward?

Natarajan

2012

Indian J Ophthalmol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Managing patients with retinal vein occlusions: Is there any real step forward?

Natarajan

2012

Indian J Ophthalmol

View full text Add to dashboard Cite

“…They also reported that intravitreal injection of anti-VEGF agent might suppress VMIAs, including ERM formation. On the other hand, there have been reports of secondary ERM formation after intravitreal anti-VEGF injection [14][15][16] . Anti-VEGF has been reported to cause hypoxia in vascular endothelial cells and increase the expression of connective tissue growth factor (CTGF), which plays an important role in tissue fibrosis and ERM formation 16 .…”

Section: Discussionmentioning

confidence: 99%

Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema

Kang

Park

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Demographics of patient. One hundred thirty-four patients were initially enrolled, but 39 patients were excluded. Thus, a total of 95 patients (147 eyes) were enrolled in this study. The demographic and clinical characteristics of all patients are summarized in Table 1. Among the 95 patients (147 eyes), 46 were male, and 49 were female. The mean age of all patients was 59.7 ± 12.7 years, and the duration of diabetes mellitus was 15.3 ± 8.6 years. Thirty-five patients had hypertension,

show abstract

“…It has been suggested that non‐selective or pan‐VEGF blockade may be detrimental due to blocking neuroprotective isoforms of VEGF essential in retinal homeostasis, adaptive response to ischaemic insult and prevention of apoptosis . Further, anti‐VEGF mediated decreases in nitrous oxide production by endothelial cells may exacerbate macular ischaemia and reduce collateral formation …”

Section: Treatmentmentioning

confidence: 99%

“…127 Further, anti-VEGF mediated decreases in nitrous oxide production by endothelial cells may exacerbate macular ischaemia and reduce collateral formation. 128,129 Ranibizumab (Lucentis) and off-label bevacizumab (Avastin), both non-selective pan-anti-VEGF agents, have taken the retinal world by storm. Intravenous bevacizumab at the oncologic dosage of 5.0 mg/kg reduces macular oedema and improves VA in neovascular AMD.…”

Section: Treatmentmentioning

confidence: 99%

The ABCs of RVO: A review of retinal venous occlusion

MacDonald¹

2014

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Retinal vein occlusions are important causes of loss of vision; indeed, they are the second most common retinal vascular disease, following diabetic retinopathy. For this reason alone, primary eye-care providers must be well versed in diagnosis and management. Risk factors, though not universally agreed upon, include but are not limited to advancing age, systemic hypertension, arteriolarsclerosis, diabetes, hyperlipidaemia, blood hyperviscosity, thrombophilia, ocular hypertension and glaucoma. Typically, visual loss is secondary to macular oedema and/or retinal ischaemia. Treatment modalities have included observation, systemic thrombolysis and haemodilution, radial optic neurotomy, chorioretinal anastomosis, vitrectomy, laser photocoagulation and intravitreal injection of anti-inflammatory and, most recently, anti-vascular endothelial growth factors.

show abstract

Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?

Abstract: Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.

Cited by 19 publications

References 24 publications

Managing patients with retinal vein occlusions: Is there any real step forward?

Managing patients with retinal vein occlusions: Is there any real step forward?

Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema

The ABCs of RVO: A review of retinal venous occlusion

Contact Info

Product

Resources

About